Volume 85 Issue 7 | p. 49 | Concentrates
Issue Date: February 12, 2007

GSK Signs For Two Late-Stage Compounds

Department: Business

GlaxoSmithKline has agreed to codevelop XenoPort's XP13512, a prodrug of the pain treatment gabapentin that improves gabapentin's bioavailability. XP13512 is in Phase III trials for restless legs syndrome. XenoPort will get an up-front payment of $78 million and could reap milestone and other payments of up to $580 million. Separately, GSK will commercialize Fabre-Kramer Pharmaceuticals' gepirone ER, a 5HT1a agonist expected to be submitted to FDA this quarter as a treatment for major depressive disorder. Financial terms weren't disclosed.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment